Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia – Pharmaceutical Technology

Alemtuzumab is being tested in a Phase I trial along with Cellectis’ CAR T-cell therapy UCART22. Image credit: Shutterstock / Nemes Laszlo. The US Food

August 2, 2024

MitraClip Shines in Real-World, Core-Lab Data

PHOENIX — Newer MitraClip devices reduced mitral regurgitation (MR) to no more than a trace for nearly all patients, regardless of anatomical complexity or presence

June 9, 2023

Brent Saunders keeps rolling out the changes at Bausch + Lomb; Incyte CSO to exit next month

→ Bausch + Lomb CEO Brent Saunders told Andrew Dunn on Wednesday that he’d take time to “digest” the $1.75 billion deal he made for

August 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.